What are California’s 2026 Healthcare Law Changes?
This article was originally published by Much Shelist, P.C. Read it on the Much website.
Fenton Jurkowitz has closed its operations. Benjamin Fenton, Nick Jurkowitz, Henry Fenton, Herbert Weinberg, Nishka Khanna, and Anne Schneider are now attorneys at Much. As we enter this exciting chapter, we thank our clients and friends for their support. Our attorneys continue to represent health care companies in matters ranging from complex litigation and compliance to license defense and transactions, now with the full-service capabilities of the Much platform.
California’s 2026 healthcare laws introduce significant changes that will affect transactions, provider autonomy, and the use of emerging technologies. With expanded regulatory oversight, stricter corporate practice rules, and new requirements impacting drug costs and AI tools, California healthcare organizations face a more complex compliance landscape.
Below, we summarize the new healthcare laws and their practical implications for providers.
What are the New Healthcare Laws in California?
Assembly Bill 1415 — Expanded Authority of the Office of Health Care Affordability (OHCA)
This law broadens reporting and advance notice requirements for a wide range of healthcare transactions, including:
- Physician practice acquisitions
- Mergers and consolidations
- Certain management services organization (MSO) arrangements
- Transactions involving private equity or investor-backed entities
OHCA now has enhanced authority to evaluate the impact of these transactions on cost, access, and quality of care.
What this means for providers:
Healthcare entities pursuing strategic transactions should anticipate longer timelines, expanded disclosure obligations, and potential regulatory scrutiny. Having an experienced healthcare attorney review your transactions is crucial to help providers stay in compliance with Assembly Bill 1415.
Senate Bill 351 — Strengthening Corporate Practice of Medicine Protections
The legislation restricts the degree of control that non-clinical entities, including private equity firms and MSOs may exercise over medical and dental practices. Specifically, it prohibits interference in:
- Clinical decision-making
- Billing practices tied to clinical judgment
- Staffing decisions
- Physician compensation structures that could influence care
- Overall professional autonomy
Additionally, the law invalidates contractual provisions that:
- Limit a physician’s ability to report quality-of-care concerns
- Restrict a physician’s ability to compete after leaving a practice
What this means for providers:
Existing MSO and private equity arrangements should be reviewed promptly. Contracts may require restructuring to ensure regulatory compliance and to reinforce physician independence. Failure to act could expose organizations to enforcement risk.
Senate Bill 40 — Insulin Cost-Sharing Limits
Beginning January 1, 2026, patient cost-sharing for insulin is limited to $35 for a 30-day supply. The law also:
- Restricts step therapy protocols
- Requires coverage of at least one form of each insulin type
What this means for providers:
While primarily directed at payors, these changes may affect prescribing practices, formulary expectations, and patient adherence. Providers should prepare for shifts in utilization patterns and patient cost concerns.
Senate Bill 41 — Pharmacy Benefit Manager (PBM) Oversight
SB 41 imposes new regulatory standards on pharmacy benefit managers, addressing:
- Pricing transparency
- Conflict-of-interest safeguards
- Greater clarity in reimbursement structures
What this means for providers:
Although implementation details will continue to evolve, providers may see downstream impacts in reimbursement rates, formulary design, and patient out-of-pocket costs. Organizations should monitor payer communications closely and adjust financial planning accordingly.
Assembly Bill 489 — Restrictions on AI Representing Clinical Authority
This law prohibits AI systems from presenting themselves as licensed healthcare professionals. Any AI-generated communication must clearly disclose that a physician or licensed clinician did not produce it.
This applies to:
- Chatbots
- Triage tools
- Patient messaging systems
- Other AI-driven clinical support platforms
What this means for providers:
Healthcare organizations deploying AI must implement clear disclosure protocols and review patient-facing communications to avoid misleading representations. Compliance failures could create both regulatory exposure and malpractice risk.
Key Takeaways for Healthcare Providers
California’s 2026 legal landscape signals a more regulated, transparency-driven healthcare environment. Providers should prioritize:
- Transaction readiness: Build compliance into deal timelines and documentation
- Contract review: Reassess MSO and investor agreements for corporate practice compliance
- Operational alignment: Monitor prescription drug policy changes and payer responses
- Technology governance: Implement safeguards for AI tools used in patient care
Speak to a California Healthcare Practice Attorney
Legal guidance is essential to navigating these changes effectively. Proactive compliance efforts today can reduce risk, protect operational flexibility, and support high-quality patient care.
Fenton Jurkowitz Law Group has a team of seasoned healthcare attorneys who can help ensure compliance and mitigate risk when navigating new healthcare laws. Fill out our contact form on our website to connect with a healthcare practice attorney today.